{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:56:25Z","timestamp":1792457785501,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1093\/rheumatology\/key309","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T16:14:42Z","timestamp":1537373682000},"page":"441-446","source":"Crossref","is-referenced-by-count":30,"title":["Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis"],"prefix":"10.1093","volume":"58","author":[{"given":"Jocelyn H","family":"Leu","sequence":"first","affiliation":[{"name":"Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omoniyi J","family":"Adedokun","sequence":"additional","affiliation":[{"name":"Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Gargano","sequence":"additional","affiliation":[{"name":"Clinical Biostatistics, Janssen Research & Development, LLC, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C","family":"Hsia","sequence":"additional","affiliation":[{"name":"Immunology, Janssen Research & Development, LLC, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopi","family":"Shankar","sequence":"additional","affiliation":[{"name":"Biologics Development Sciences, Janssen Research & Development, LLC, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"key\n\t\t\t\t2019022006303499700_key309-B1","volume-title":"Guidance for industry assay development for immunogenicity testing of therapeutic proteins","year":"2009"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products","volume":"289","author":"Mire-Sluis","year":"2004","journal-title":"J Immunol Methods"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor \u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/ard.2009.116319","article-title":"Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study","volume":"69","author":"Keystone","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B6","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B7","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B9","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/art.21243","article-title":"Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor","volume":"52","author":"Siegel","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B10","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B11","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/ard.2009.108787","article-title":"Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis","volume":"69","author":"van Kuijk","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B14","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B15","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/ar3386","article-title":"Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases","volume":"13","author":"Ducourau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"AAPS J"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1208\/s12248-015-9857-y","article-title":"Evaluating and reporting the immunogenicity impacts for biological products\u2014a clinical pharmacology perspective","volume":"18","author":"Wang","year":"2016","journal-title":"AAPS J"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1208\/s12248-012-9408-8","article-title":"Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics","volume":"15","author":"Zhou","year":"2013","journal-title":"AAPS J"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","article-title":"Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context","volume":"39","author":"Bloem","year":"2017","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t2019022006303499700_key309-B20","doi-asserted-by":"crossref","first-page":"3072586","DOI":"10.1155\/2016\/3072586","article-title":"Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance","volume":"2016","author":"Song","year":"2016","journal-title":"J Immunol Res"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/3\/441\/27900770\/key309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T15:03:03Z","timestamp":1550674983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/3\/441\/5167193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,11,8]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key309","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,11,8]]}}}